Further research could clarify whether A20 protein is altered in macrophages and possibly other types of antigen presenting cells in MS patients and whether A20 expression correlates to different stages or activity of the disease or responsiveness to specific immunomodulatory treatment. Here, TNFAIP3 is linked to myeloid sarcoma.